



Biotech Daily

Friday May 4, 2012

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: ANTISENSE UP 20%, NEUREN DOWN 7%**
- * **NANOSONICS PLACEMENT RAISES \$15.5m, SHARE PLAN**
- * **ANTISENSE RAISES \$5m OF EXPECTED \$6.5m**
- * **US PATENT FOR ANTEO'S MIX&GO BIO-GLUE**
- * **JASON PETERSON, CELTIC CAPITAL BELOW 5% OF ACUVAX**

MARKET REPORT

The Australian stock market fell 0.75 percent on Friday May 4, 2012 with the S&P ASX 200 down 33.0 points to 4,396.0 points.

Eleven of the Biotech Daily Top 40 stocks were up, 18 fell, seven traded unchanged and four were untraded. All three Big Caps fell.

Antisense was the best, up 0.3 cents or 20 percent to 1.8 cents with 27.5 million shares traded, followed by Impedimed up 12.2 percent to 41.5 cents with 21,000 shares traded and Nanosonics up 10 percent to 55 cents with 183,778 shares traded.

Allied Health climbed 7.4 percent; Benitec was up 5.3 percent; Genera was up 4.2 percent; Tissue Therapies was up 3.7 percent; Prima and Viralytics rose more than two percent; Living Cell was up 1.6 percent; with Sirtex up half a percent.

Neuren led the falls, down 0.2 cents or 7.4 percent to 2.5 cents with 7.1 million shares traded.

Avita, Phosphagenics and Universal Biosensors lost more than six percent; Alchemia was down 5.1 percent; Bioniche, Bionomics and Genetic Technologies fell more than four percent; Patrys and Phylogica were down more than three percent; Psivida and Resmed shed more than two percent; CSL, QRX and Reva were down more than one percent; with Acrux, Cochlear, Heartware, Mesoblast, Pharmaxis and Starpharma down by less than one percent.

NANOSONICS

Nanosonics says it has raised \$15.5 million through a placement at 53 cents a share and will offer a share purchase plan.

Nanosonics said the placement to institutional and sophisticated investors was led by Allan Gray (formerly Orbis) with Shaw Corporate as participating broker.

The placement at 53 cents was a six percent premium to the company's closing price prior to the announcement.

The company said that the share purchase plan would allow shareholders at the record date of May 3, 2012 to apply for new shares at 53 cents each, but did not provide further details saying they would be released next week.

Nanosonics the funds would be used for working capital to support sales, distributor and marketing programs, investment in expanding direct sales resources in key markets, continued investment in development of promising additional products and scaling-up manufacturing.

Nanosonics was up five cents or 10 percent to 55 cents.

ANTISENSE THERAPEUTICS

Antisense says the second tranche of its proposed \$6.5 million capital raising has been completed, raising a total of \$5 million (BD: Mar 23, 2012).

In March the company said it had raised \$6.5 million through a \$4.5 million placement at 1.8 cents a share and an underwritten \$2 million share purchase plan with Patersons Securities as the underwriter.

After the market closed on April 24, before the Anzac Day public holiday, Antisense told the ASX that \$500,000 of the \$2 million share plan had been subscribed and the underwriting agreement would not proceed.

Antisense said that with Patersons Securities it had considered extending the share plan but the board decided not to extend the closing date and that because of the company's share price, Patersons underwriting would not proceed.

Antisense was up 0.3 cents or 20 percent to 1.8 cents with 27.5 million shares traded.

ANTEO DIAGNOSTICS

Anteo says the US Patent & Trademark Office has granted the 'Use of Metal Complexes' patent for its Mix&Go technology binding biological molecules to synthetic materials.

Anteo said the patent was issued on May 1, 2012 and the USPTO determined that an additional 864 days were required to be added onto the term of the patent due to delays during examination.

The company said that a divisional application from the 'Use of Metal Complexes' patent had been filed, with details expected to be published once formalities were completed.

Anteo said there were "many commercially important reasons to bind biological molecules onto synthetic materials ... [and] molecules are often fragile and do not react well when exposed to non-biological conditions".

The company said that Mix&Go had been demonstrated to allow biological molecules to retain their activity when bound.

Anteo chief executive officer Dr Geoff Cumming said the patent was "particularly pleasing given the scale of the biotechnology sector in the United States".

Anteo closed unchanged at 7.7 cents with two million shares traded.

ACUVAX

Jason Peterson and Celtic capital have reduced below five percent in Acuvax.

The change of substantial shareholder notice said Celtic Capital and Mr Peterson had sold 101,376,316 shares for \$101,376 or 0.1 cents a share.

The previous substantial shareholder notice said that celtic and Mr Peterson held 152,000,000 shares or 6.2 percent (BD: Sep 9, 2011).

Acuvax was untraded at 0.1 cents.